Darae Strategic Commercialization Center Co., Ltd. (CEOs Bae Sun-gu and Kim Jeong-guk), a leading expert in tecnología-based listing consulting, and RudaCure Inc. (CEO Yongho Kim), a drug developer targeting trastorno sensorial diseases, have solidified their strategic asociación.
On the 4th, the two empresas firmó unn 'MOU for IP Portfolio Strategy Development and Technology-Based Listing Evaluation Consulting for RudaCure Inc.'
A través de esto MOU and inversión, Darae Strategic Commercialization Center proporcionará comprehensive consulting to RudaCure Inc.—which está planificando a tecnología-based listing—including mock evaluacións for tecnología-based listing, IP portfolio and I+D strategy, and inversión apoyo, in order to help RudaCure Inc. successfully achieve a stable tecnología-based listing with its excellent technologies and drugs.
Darae Strategic Commercialization Center holds the highest reputation in the pharmaceutical and bio consulting industria, consulting dozens of pharmaceutical and bio empresas each year. It provides a wide range of consulting services including tecnología-based listing consulting, IP consulting, I+D strategy, and tecnología valuation, and también actively involved as an accelerator and investor. Recientemente, la empresa ha sido concentrating its capabilities on tecnología-based listing consulting for pharmaceutical and bio empresas.
RudaCure Inc. has already had licensing experience with tratamiento de la enfermedad de ojo secos and daño corneal tratamientos in 2021 and 2023, and actualmente está developing a best-in-class powerful analgésico no narcótico. La empresa está desarrollando innovador drugs for various intractable diseases targeting GTPase and canal iónicos, and is actively conducting investigación on psoriasis, atopic dermatitis, and anticancer agents. As a bio-venture company pursuing continuous crecimiento through investigación conjunta and codesarrollo with nacional e internacional empresas farmacéuticas, RudaCure is well-positioned for future expansion.
RudaCure Inc. CEO Yongho Kim dijo, "Through substantive mutual cooperación with Darae Strategic Commercialization Center, with whom we have built a relationship durante los últimos three years, we will grow into a bio-venture company with even stronger propiedad intelectual and differentiated technologies en el futuro," expressing expectations for the strategic colaboración.
RudaCure Inc. actualmente está identifying compuestos effective for chemotherapy-induced and cancer-related pain, and está preparando to present the tecnología at the 2023 ASCO conferencia. As a member of the ensayo clínico delegation, la empresa planea simultaneously engage in exchange and tecnología promotion regarding anticancer ensayo clínicos on-site.
Yakup Sinmun: RudaCure "Formally begins preparations for tecnología-based IPO listing"